Status:
TERMINATED
Statin in Hip Fracture
Lead Sponsor:
University Hospital, Brest
Collaborating Sponsors:
Ministry of Health, France
Conditions:
Hip Fracture
Eligibility:
All Genders
60+ years
Phase:
PHASE3
Brief Summary
Statins (or HMG-CoA reductase inhibitors) have largely proven their efficacy in the primary and secondary prevention of cardiovascular events. Many clinical and experimental studies support also a pot...
Eligibility Criteria
Inclusion
- 60 years old or older.
- fracture of the femoral neck or of the trochanteric mass
- undergoing surgery within 5 days for this fracture
- Signed written informed consent
Exclusion
- contraindication to rosuvastatin:
- active liver disease including unexplained and prolonged elevations of serum transaminases and any increase of serum transaminases beyond 3 times the upper limit of normal
- severe renal impairment (creatinine clearance calculated by the formula MDRD \<30 ml / min)
- myopathy
- use of cyclosporine
- statin therapy ongoing at the admission for fracture
- curative anticoagulant therapy ongoing at the admission and expected to be maintained after the intervention
- Patients considered by the investigator to be unable to participate to the study
- Refuse to participate
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01494090
Start Date
August 1 2011
End Date
September 1 2012
Last Update
September 20 2012
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Brest, University Hospital
Brest, France
2
Caen, University Hospital
Caen, France
3
Grenoble, University Hospital
Grenoble, France
4
APHP - Cochin Hospital
Paris, France